SuperworthSyndax Pharmaceuticals EPS SNDX
Diluted earnings per share by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- −$2.51
- Latest quarter, Q2 FY26
- −$0.55
- Fiscal year 2025
- −$3.29
Syndax Pharmaceuticals' earnings per share was −$2.51 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.55.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.29 | n/a |
| FY2024 | −$3.72 | n/a |
| FY2023 | −$2.96 | n/a |
| FY2022 | −$2.45 | −745% |
| FY2021 | $0.38 | n/a |
| FY2020 | −$1.88 | n/a |
| FY2019 | −$1.85 | −164% |
| FY2018 | $2.91 | n/a |
| FY2017 | −$4.96 | n/a |
| FY2016 | −$4.75 | n/a |
| FY2015 | −$1543.24 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.55 | n/a | −$2.51 | |
| Q1 FY26 | −$0.48 | n/a | −$2.79 | |
| Q4 FY25 | −$0.78 | n/a | −$3.29 | |
| Q3 FY25 | −$0.70 | n/a | −$3.60 | |
| Q2 FY25 | −$0.83 | n/a | −$3.88 | |
| Q1 FY25 | −$0.98 | n/a | −$3.85 | |
| Q4 FY24 | −$1.09 | n/a | −$3.72 | |
| Q3 FY24 | −$0.98 | n/a | −$3.63 | |
| Q2 FY24 | −$0.80 | n/a | −$3.38 | |
| Q1 FY24 | −$0.85 | n/a | −$3.22 | |
| Q4 FY23 | −$1.00 | n/a | −$2.96 | |
| Q3 FY23 | −$0.73 | n/a | −$2.58 |
Against its peers
Companies in Drug Manufacturers - General nearest Syndax Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SNDXSyndax Pharmaceuticals | −$2.51 | |
| OMEROmeros | $1.52 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| ABUSArbutus Biopharma | $0.78 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| Peer median | $2.07 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Syndax Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.